Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection

Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection

Middle East respiratory syndrome (MERS) continues to raise worldwide concerns due to its pandemic potential. Increased MERS cases and no licensed MERS vaccines highlight the need to develop safe and effective vaccines against MERS. We have previously demonstrated that a receptor-binding domain (RBD)...

Full description

Bibliographic Details
Main Authors: Yufei Wang, Wanbo Tai, Jie Yang, Guangyu Zhao, Shihui Sun, Chien-Te K. Tseng, Shibo Jiang, Yusen Zhou, Lanying Du, Jimin Gao
Format: Article
Language:English
Published: Taylor & Francis Group 2017-07-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
hdpp4-transgenic mice
mers-cov
neutralizing antibodies
optimal immunogen dosage
optimal immunization interval
protection
receptor-binding domain
Online Access:http://dx.doi.org/10.1080/21645515.2017.1296994

Internet

http://dx.doi.org/10.1080/21645515.2017.1296994

Similar Items